We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. 82.8% of patients treated with Vtama achieved the ...
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis. I think a survey like ...
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in ...
Roflumilast cream may be suitable for chronic treatment, including the face and intertriginous areas, according to one study. Once-daily roflumilast cream 0.3% in adults with chronic plaque psoriasis ...
Intertriginous plaque psoriasis, also known as inverse psoriasis, affects approximately 20%–30% of individuals who have plaque psoriasis. The treatment for plaque psoriasis in intertriginous areas is ...
WESTLAKE VILLAGE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...
The US Food and Drug Administration (FDA) has approved roflumilast 0.3% cream for the topical treatment of plaque psoriasis, "including intertriginous areas," in patients aged 12 years and older.
A 25-year-old woman receiving daily prednisolone treatment for systemic lupus erythematosus presented with a 3-month history of erosive, violaceous plaques in the antecubital fossae, popliteal foss ...
The woman had axillary granular parakeratosis (GP), a benign condition. First described in 1991, this disease presents with erythematous hyperpigmented and hyperkeratotic papules and plaques in ...
Credit: Arcutis Biotherapeutics. The approval was based on data from the two phase 3 trials that included patients aged 12 years and older with mild to severe plaque psoriasis. The Food and Drug ...
A 55-year-old woman was referred to the dermatology department for an intertriginous eruption of one week’s duration. She had undergone breast-conserving surgery for stage 2 breast cancer. Two weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results